GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Compan ...
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of immune ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as NAFLD, represents the most prevalent liver disorder globally, ...
On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments. The study ...
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful ...
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful ...
BioWorld - Thursday, October 23, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Study evaluates allogeneic ...
AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results